Skip to main content

Table 1 Studies on mutation status of KRAS , BRAF and PIK3CA in Chinese CRC patients

From: BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients

Reference (year)

No. of patients

Method

Mutation frequencies

Region

Prognostic value

[2] Gao J., et al. (2011)

273

Direct sequencing

KRAS (38.5%); BRAF (5.1%)

Chinese

 

[24] Li H.T., et al. (2011)

200

Pyrosequencing

KRAS (31.5%); BRAF (7.0%); PIK3CA (12.5%)

Chinese

KRAS and PIK3CA bi-mutations were more likely to develop liver metastases.

[25] Shen H., et al. (2011)

118

Pyrosequencing

KRAS (34.7%); BRAF (1.7%)

Chinese

 

[26] Liou J.M., et al. (2011)

314

Direct sequencing

KRAS (20.7%); BRAF (3.8%)

Taiwan

BRAF mutation was associated with worse overall survival.

[27] Mao C., et al. (2012)

69

Direct sequencing

KRAS (43.9%); BRAF (25.4%); PIK3CA (8.2%)

Chinese

 

[28] Hsieh L.L., et al. (2012)

182

Direct sequencing & HRM

KRAS (33.5%); BRAF (1.1%); PIK3CA (7.1%)

Taiwan

 

[29] Zhu Y.F., et al. (2012)

60

Direct sequencing

PIK3CA (21.6%)

Chinese

High PI3K expression was associated with CRC metastases.

[30] Li Z., et al. (2012)

78

Direct sequencing

KRAS (33.3%)

Chinese

KRAS mutations were associated with poor survival and liver metastasis.

[31] Shen Y., et al. (2013)

676

Direct sequencing

KRAS (35.9%); BRAF (6.96%); PIK3CA (9.9%)

Chinese

 

[32] Pu X., et al. (2013)

115

Direct sequencing

KRAS (32.2%); BRAF (3.5%)

Chinese

 

[33] Wang J., et al. (2013)

574

Direct sequencing

KRAS (34.2%)

Chinese

 

[34] Chang Y.S., et al. (2013)

165

HRM

KRAS (36.97%); BRAF (4.24%)

Taiwan

KRAS mutation was associated with poor survival.